Free Trial
NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

Autolus Therapeutics logo
$2.37 +0.02 (+0.85%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$2.37 0.00 (0.00%)
As of 07/3/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Autolus Therapeutics Stock (NASDAQ:AUTL)

Key Stats

Today's Range
$2.32
$2.38
50-Day Range
$1.19
$2.37
52-Week Range
$1.11
$5.00
Volume
451,120 shs
Average Volume
1.58 million shs
Market Capitalization
$630.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.32
Consensus Rating
Buy

Company Overview

Autolus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

AUTL MarketRank™: 

Autolus Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 1420th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Autolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Autolus Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Autolus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Autolus Therapeutics is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Autolus Therapeutics is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Autolus Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Autolus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.43% of the float of Autolus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Autolus Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Autolus Therapeutics has recently increased by 9.85%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Autolus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Autolus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.43% of the float of Autolus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Autolus Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Autolus Therapeutics has recently increased by 9.85%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Autolus Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Autolus Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 9 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Autolus Therapeutics' insider trading history.
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AUTL Stock News Headlines

Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.
Autolus Therapeutics plc (AUTL) - Yahoo Finance
See More Headlines

AUTL Stock Analysis - Frequently Asked Questions

Autolus Therapeutics' stock was trading at $2.35 at the beginning of 2025. Since then, AUTL shares have increased by 0.9% and is now trading at $2.37.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) issued its earnings results on Thursday, May, 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The business earned $8.98 million during the quarter, compared to analysts' expectations of $1.59 million.
Read the conference call transcript
.

Autolus Therapeutics (AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
5/08/2025
Today
7/04/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.32
High Stock Price Target
$13.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+293.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$220.66 million
Pretax Margin
-2,600.95%

Debt

Sales & Book Value

Annual Sales
$10.12 million
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
1.47

Miscellaneous

Free Float
197,743,000
Market Cap
$630.75 million
Optionable
Optionable
Beta
1.81
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:AUTL) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners